Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00634985 |
To assess the safety and efficacy of eletriptan for the treatment of migraine in subjects who had not been adequately treated with non-steroidal antiinflammatory drugs (NSAIDs)
Condition | Intervention | Phase |
---|---|---|
Migraine |
Drug: eletriptan |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Multicentre, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Eletriptan 40 Mg for the Treatment of Migraine (With or Without Aura) in Subjects Unsuccessfully Treated With NSAIDS |
Enrollment: | 106 |
Study Start Date: | November 2002 |
Study Completion Date: | December 2003 |
Arms | Assigned Interventions |
---|---|
A: Experimental |
Drug: eletriptan
40 mg oral tablet for migraine attack; additional 40 mg oral tablet >2 hours from first dose if migraine reoccurred within 24 hours of achieving response
|
Ages Eligible for Study: | 18 Years to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Turkey | |
Pfizer Investigational Site | |
ISTANBUL, Turkey | |
Pfizer Investigational Site | |
IZMIR, Turkey | |
Pfizer Investigational Site | |
SAMSUN, Turkey | |
Pfizer Investigational Site | |
GAZIANTEP, Turkey | |
Turkey, ANKARA | |
Pfizer Investigational Site | |
Unknown, ANKARA, Turkey | |
Turkey, ISTANBUL | |
Pfizer Investigational Site | |
CAPA, ISTANBUL, Turkey | |
Turkey, MANISA | |
Pfizer Investigational Site | |
Unknown, MANISA, Turkey |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Responsible Party: | Pfizer, Inc ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A1601085 |
Study First Received: | March 3, 2008 |
Last Updated: | April 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00634985 History of Changes |
Health Authority: | Turkey: Ministry of Health, Central Ethics Committee |
Serotonin Agonists Eletriptan Anti-Inflammatory Agents Neurotransmitter Agents Central Nervous System Diseases Headache Disorders, Primary Brain Diseases Serotonin |
Headache Disorders Migraine Disorders Analgesics, Non-Narcotic Headache Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents |
Serotonin Agonists Anti-Inflammatory Agents Eletriptan Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Central Nervous System Diseases Headache Disorders, Primary Brain Diseases Pharmacologic Actions |
Headache Disorders Serotonin Agents Migraine Disorders Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents |